Blar i Bergen Open Research Archive på forfatter "Torkildsen, Øivind"
-
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig; Bindoff, Laurence; Kuhle, Jens; Vedeler, Christian A. (Peer reviewed; Journal article, 2018)Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed ... -
No association of tobacco use and disease activity in multiple sclerosis
Kvistad, Silje; Myhr, Kjell-Morten; Holmøy, Trygve; Saltyte Benth, Jurate; Løken-Amsrud, Kristin Ingeleiv; Wergeland, Stig; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Bakke, Søren Jacob; Torkildsen, Øivind (Peer reviewed; Journal article, 2016-08)Objective: To study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS). Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally ... -
Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro
Førde, Jan-Lukas; Herfindal, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Mollnes, Tom Eirik; Skrede, Silje (Journal article; Peer reviewed, 2023)The clinical and adverse effects of the therapeutic monoclonal antibodies (mAb) ocrelizumab, ofatumumab and rituximab in multiple sclerosis (MS) are presently subject to extensive study. While the two former are approved ... -
Predictors of hospitalization due to infection in rituximab-treated MS patients
Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald; Bø, Lars; Myhr, Kjell-Morten; Torgauten, Hilde Marie; Torkildsen, Øivind; Wergeland, Stig (Journal article; Peer reviewed, 2023)Background: Rituximab is extensively used off-label to treat multiple sclerosis (MS), and long-term vigilance for adverse events is needed. This study was conducted to determine frequencies and predictors of hematological ... -
Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease
Ueland, Grethe Åstrøm; Ueland, Hans Olav; Stokland, Ann-Elin Meling; Bhan, Alok; Schønberg, Anne; Sollid, Stina Therese; Morgas, Dina Edvarda; Holmøy, Trygve; Lima, Kari; Methlie, Paal; Løvås, Kristian; Torkildsen, Øivind; Husebye, Eystein Sverre (Journal article; Peer reviewed, 2024)Objective Atypical Graves disease (GD) is a common complication in multiple sclerosis (MS) patients treated with alemtuzumab. We present epidemiological, clinical, and biochemical characteristics of alemtuzumab-induced ... -
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder
Holmøy, Trygve; Høglund, Rune Alexander; Illes, Zsolt; Myhr, Kjell-Morten; Torkildsen, Øivind (Journal article; Peer reviewed, 2020)Background Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been based on retrospective case series. The results of six randomized clinical trials including five different monoclonal antibodies ... -
Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis
Lie, Ingrid Anne; Weeda, Merlin M.; Mattiesing, Rozemarijn M.; Mol, Marijke A.E.; Pouwels, Petra J.W.; Barkhof, Frederik; Torkildsen, Øivind; Bø, Lars; Myhr, Kjell-Morten; Vrenken, Hugo (Journal article; Peer reviewed, 2022)Background and Objectives: There is currently no consensus about the extent of gray matter (GM) atrophy that can be attributed to secondary changes after white matter (WM) lesions or the temporal and spatial relationships ... -
Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ... -
Safety of breast feeding during rituximab treatment in multiple sclerosis
Rød, Brit Ellen; Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars; Wergeland, Stig (Journal article; Peer reviewed, 2022)Background There are limited data on the safety of breast feeding during rituximab therapy. Our objective is to determine exposure from breast feeding and biological effects of rituximab in breastfed infants. Methods ... -
Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades
Grytten, Nina; Torkildsen, Øivind; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2015-06-05)Norway has been subjected to numerous epidemiological investigations on the prevalence and incidence of multiple sclerosis (MS), dating back to 1935. The objective of this study was to review the studies on the prevalence ... -
A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS
Skorve, Ellen; Lundervold, Astri; Torkildsen, Øivind; Myhr, Kjell-Morten (Journal article; Peer reviewed, 2020)Background: Cognitive impairment is common in patients with multiple sclerosis (MS) and may occur at any stage and with any subtype of the disease. Screening and monitoring of cognitive function should therefore be implemented ... -
An Update on Vitamin D and Disease Activity in Multiple Sclerosis
Smolders, Joost; Torkildsen, Øivind; Camu, William; Holmøy, Trygve (Peer reviewed; Journal article, 2019)Vitamin D and its main active metabolite 1,25-dihydroxyvitamin D serve a crucial role in maintenance of a healthy calcium metabolism, yet have additional roles in immune and central nervous system cell homeostasis. Serum ...